cancer drugs

Top Considerations in Pediatric Cancer Treatment: What Payers Should KnowA Stanford expert describes ideal treatment locations, common barriers, and how payers could better support patients and families.
Five factors driving up the cost of oncology drugsThe high cost of specialty drugs continues to plague the healthcare industry. Here’s why.
Managing cancer treatment side effects: What payers should knowMoffitt Cancer Center expert shares her thinking on managing chemotherapy-related side effects.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
The Latest 10 Novel FDA Drug Approvals
The Latest 10 Novel FDA Drug ApprovalsWhat you need to know about the latest new medications.
Five rules for payer success in oncologyPayers must reinvent efforts to reduce cancer cost and increase quality for a value-based care world. Here’s five rules to follow.
Innovative strategies help fight multiple myeloma: What every exec should knowAs new scientific advancements occur at the genetic and protein levels, more strategies have been developed to identify and combat multiple myeloma.
First drug for rare skin cancer wins approvalFDA approved the first treatment for metastatic Merkel cell carcinoma (MCC), a rare, aggressive skin cancer.
Top challenges in cancer careCancer drug costs remain the most critical challenge in care, among other things.